Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine

L. T. Wu, Peter Vytautas Dicpinigaitis, H. Bruckner, W. Manger, S. Averbuch

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) is an effective treatment regimen for malignant pheochromocytoma. There have not been any significant acute cardiovascular effects reported following CVD treatment. Among seven patients with malignant pheochromocytoma treated with CVD at our institution, two patients with labile hypertension developed hypertensive crises following CVD treatment. The marked increase in blood pressure correlated with an increase in urinary excretion of catecholamine metabolites in one patient. Further hypertensive crises following subsequent CVD treatments were avoided by optimizing each patient's antiadrenergic therapy. Similar to the approach used preoperatively for patients with resectable pheochromocytoma, maximal antiadrenergic therapy is essential in preventing hypertensive crises in patients with malignant pheochromocytoma undergoing CVD treatment.

Original languageEnglish (US)
Pages (from-to)389-392
Number of pages4
JournalMedical and Pediatric Oncology
Volume22
Issue number6
StatePublished - 1994
Externally publishedYes

Fingerprint

Dacarbazine
Pheochromocytoma
Vincristine
Cyclophosphamide
Adrenergic Antagonists
Therapeutics
Combination Drug Therapy
Catecholamines
Blood Pressure
Hypertension

Keywords

  • chemotherapy
  • cyclophosphamide
  • dacarbazine
  • hypertensive crises
  • malignant pheochromocytoma
  • vincristine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine. / Wu, L. T.; Dicpinigaitis, Peter Vytautas; Bruckner, H.; Manger, W.; Averbuch, S.

In: Medical and Pediatric Oncology, Vol. 22, No. 6, 1994, p. 389-392.

Research output: Contribution to journalArticle

@article{8c77344e82a940a584e2f1004e47aaa3,
title = "Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine",
abstract = "Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) is an effective treatment regimen for malignant pheochromocytoma. There have not been any significant acute cardiovascular effects reported following CVD treatment. Among seven patients with malignant pheochromocytoma treated with CVD at our institution, two patients with labile hypertension developed hypertensive crises following CVD treatment. The marked increase in blood pressure correlated with an increase in urinary excretion of catecholamine metabolites in one patient. Further hypertensive crises following subsequent CVD treatments were avoided by optimizing each patient's antiadrenergic therapy. Similar to the approach used preoperatively for patients with resectable pheochromocytoma, maximal antiadrenergic therapy is essential in preventing hypertensive crises in patients with malignant pheochromocytoma undergoing CVD treatment.",
keywords = "chemotherapy, cyclophosphamide, dacarbazine, hypertensive crises, malignant pheochromocytoma, vincristine",
author = "Wu, {L. T.} and Dicpinigaitis, {Peter Vytautas} and H. Bruckner and W. Manger and S. Averbuch",
year = "1994",
language = "English (US)",
volume = "22",
pages = "389--392",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine

AU - Wu, L. T.

AU - Dicpinigaitis, Peter Vytautas

AU - Bruckner, H.

AU - Manger, W.

AU - Averbuch, S.

PY - 1994

Y1 - 1994

N2 - Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) is an effective treatment regimen for malignant pheochromocytoma. There have not been any significant acute cardiovascular effects reported following CVD treatment. Among seven patients with malignant pheochromocytoma treated with CVD at our institution, two patients with labile hypertension developed hypertensive crises following CVD treatment. The marked increase in blood pressure correlated with an increase in urinary excretion of catecholamine metabolites in one patient. Further hypertensive crises following subsequent CVD treatments were avoided by optimizing each patient's antiadrenergic therapy. Similar to the approach used preoperatively for patients with resectable pheochromocytoma, maximal antiadrenergic therapy is essential in preventing hypertensive crises in patients with malignant pheochromocytoma undergoing CVD treatment.

AB - Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) is an effective treatment regimen for malignant pheochromocytoma. There have not been any significant acute cardiovascular effects reported following CVD treatment. Among seven patients with malignant pheochromocytoma treated with CVD at our institution, two patients with labile hypertension developed hypertensive crises following CVD treatment. The marked increase in blood pressure correlated with an increase in urinary excretion of catecholamine metabolites in one patient. Further hypertensive crises following subsequent CVD treatments were avoided by optimizing each patient's antiadrenergic therapy. Similar to the approach used preoperatively for patients with resectable pheochromocytoma, maximal antiadrenergic therapy is essential in preventing hypertensive crises in patients with malignant pheochromocytoma undergoing CVD treatment.

KW - chemotherapy

KW - cyclophosphamide

KW - dacarbazine

KW - hypertensive crises

KW - malignant pheochromocytoma

KW - vincristine

UR - http://www.scopus.com/inward/record.url?scp=0028197410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028197410&partnerID=8YFLogxK

M3 - Article

C2 - 8152400

AN - SCOPUS:0028197410

VL - 22

SP - 389

EP - 392

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -